I9DN Stock Overview
A biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Arbutus Biopharma Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.23 |
| 52 Week High | US$4.22 |
| 52 Week Low | US$1.64 |
| Beta | 1.92 |
| 11 Month Change | -11.01% |
| 3 Month Change | -5.44% |
| 1 Year Change | 99.38% |
| 33 Year Change | 20.00% |
| 5 Year Change | 122.80% |
| Change since IPO | -22.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| I9DN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.3% | -0.7% | -0.02% |
| 1Y | 99.4% | -17.2% | 8.2% |
Return vs Industry: I9DN exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: I9DN exceeded the German Market which returned 8.2% over the past year.
Price Volatility
| I9DN volatility | |
|---|---|
| I9DN Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: I9DN has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: I9DN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 73 | Mike McElhaugh | www.arbutusbio.com |
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19.
Arbutus Biopharma Corporation Fundamentals Summary
| I9DN fundamental statistics | |
|---|---|
| Market cap | €638.71m |
| Earnings (TTM) | -€73.66m |
| Revenue (TTM) | €6.47m |
98.7x
P/S Ratio-8.7x
P/E RatioIs I9DN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| I9DN income statement (TTM) | |
|---|---|
| Revenue | US$6.74m |
| Cost of Revenue | US$62.79m |
| Gross Profit | -US$56.05m |
| Other Expenses | US$20.65m |
| Earnings | -US$76.70m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | -831.34% |
| Net Profit Margin | -1,137.64% |
| Debt/Equity Ratio | 5.0% |
How did I9DN perform over the long term?
See historical performance and comparison